U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054346) titled 'Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617' on June 28.
Brief Summary: There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer...